EyePoint Pharmaceuticals ... (EYPT)
NASDAQ: EYPT
· Real-Time Price · USD
11.09
0.24 (2.21%)
At close: Aug 15, 2025, 3:59 PM
11.09
0.05%
After-hours: Aug 15, 2025, 04:10 PM EDT
EyePoint Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -45.2M | -41.4M | -29.36M | -30.83M | -29.28M | -14.1M | -12.61M | -22.92M | -21.16M | -43.45M | -18.42M | -19.41M | -20.98M | -19.43M | -16.7M | -10.01M | -12.28M |
Depreciation & Amortization | 497K | 467K | 408K | 362K | 303K | 112K | 115K | 132K | 105K | 335K | 711K | 704K | 696K | 698K | 701K | 685K | 687K |
Stock-Based Compensation | 7.82M | 7.9M | 7.45M | 8.7M | 12.7M | 3.59M | 3.63M | 1.79M | 3.05M | 3.36M | 3.2M | 4.14M | 3.48M | 2.81M | 2.47M | 1.18M | 988K |
Other Working Capital | -23.09M | -3.46M | 17.14M | -5.46M | -8.27M | -13.4M | -13.84M | 71.79M | -62K | -1.77M | -274K | -173K | -260K | -5.26M | -233K | -217K | -278K |
Other Non-Cash Items | 6.09M | -1.72M | -28.55M | -1.01M | 18.77M | -522K | -3.72M | -51K | -244K | 22.31M | -214K | -114K | 1.67M | 166K | 162K | 153K | 147K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | 83K | 3.69M | 2.04M | n/a | n/a | n/a | n/a | n/a | 1.28M | n/a | -2.06M | n/a |
Change in Working Capital | -14.51M | -1.1M | 11.03M | 3.28M | -14.31M | -12.27M | -6.3M | 76.03M | 1.42M | 4.86M | 1.59M | -4.45M | -5.02M | -2.19M | 5.57M | -486K | -4.64M |
Operating Cash Flow | -53.12M | -35.85M | -39.03M | -20.18M | -31.17M | -23.11M | -15.2M | 57.02M | -16.84M | -12.59M | -13.14M | -19.12M | -20.16M | -16.67M | -7.79M | -10.54M | -15.1M |
Capital Expenditures | -276K | -384K | -1.57M | -900K | -1.19M | -883K | -1.72M | -396K | -484K | -585K | -1.2M | -218K | -149K | n/a | -131K | -25K | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | 46.27M | n/a | -13.86M | -244K | -558K | -7.47M | n/a | 110K | n/a | n/a | n/a | n/a |
Purchase of Investments | -39.42M | -164.08M | -49.23M | -185M | n/a | -49.27M | n/a | -2.92M | -2.93M | -13.5M | -33.53M | -29.79M | -62.29M | -32.97M | n/a | n/a | n/a |
Sales Maturities Of Investments | 79.22M | 68.5M | 62.86M | 25.5M | 22M | 3M | n/a | 16.78M | 35.5M | 47M | 41M | 30M | 6M | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | 4.14M | -159.5M | 22M | -46.27M | n/a | 13.86M | 244K | 558K | 7.47M | 206K | -110K | -32.97M | n/a | n/a | n/a |
Investing Cash Flow | 39.52M | -95.96M | 16.2M | -160.4M | 20.81M | -47.15M | -1.72M | 13.47M | 32.09M | 32.92M | 6.27M | -12K | -56.44M | -32.97M | -131K | -25K | n/a |
Debt Repayment | -35K | -32K | -73K | n/a | n/a | n/a | n/a | -35.3M | -5.18M | -34K | -36K | -34K | -87K | -44K | -44K | -40K | -18K |
Common Stock Repurchased | n/a | n/a | -78K | -78K | -4.36M | n/a | n/a | n/a | -169K | -24K | n/a | -21K | -250K | n/a | -7.22M | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -1.51M | 196K | 11.97M | 329K | 115K | 2.29M | 10.36M | -1.36M | 61K | -24K | 128K | -242K | -602K | 84K | 7.36M | -12K | -128K |
Financial Cash Flow | -951K | 151.69M | 11.89M | 329K | 115K | 218.49M | 10.36M | -36.66M | -5.12M | -58K | 92K | -276K | -448K | 108.52M | -2K | -381K | 108.77M |
Net Cash Flow | -14.55M | 19.87M | -10.79M | -180.24M | -10.25M | 148.23M | -6.56M | 33.83M | 10.13M | 20.27M | -6.77M | -19.41M | -77.05M | 58.88M | -7.92M | -10.95M | 93.67M |
Free Cash Flow | -53.4M | -36.23M | -40.6M | -21.08M | -32.37M | -23.99M | -16.92M | 56.63M | -17.32M | -13.17M | -14.33M | -19.34M | -20.31M | -16.67M | -7.92M | -10.57M | -15.1M |